Exchange: OTC·Updated 03:11 PM EDT

DBVTF DBV Technologies

$2.51
$1.75
(40.99%)
Today
EarningsOct 28
Mkt Cap$790.01M
Vol75,000.00

About DBVTF

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.
50

Neutral Sentiment

How do you feel about DBVTF?

Advertisement|Remove ads.